Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950170-23-020611
Filing Date
2023-05-10
Accepted
2023-05-10 16:36:07
Documents
16
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A pyxs-20221231.htm   iXBRL 10-K/A 104704
2 EX-31.1 pyxs-ex31_1.htm EX-31 21154
3 EX-31.2 pyxs-ex31_2.htm EX-31 19279
  Complete submission text file 0000950170-23-020611.txt   2023853

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT pyxs-20221231_def.xml EX-101.DEF 213259
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pyxs-20221231_pre.xml EX-101.PRE 399426
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT pyxs-20221231_cal.xml EX-101.CAL 50653
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pyxs-20221231_lab.xml EX-101.LAB 526994
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pyxs-20221231.xsd EX-101.SCH 63399
10 EXTRACTED XBRL INSTANCE DOCUMENT pyxs-20221231_htm.xml XML 10945
Mailing Address 321 HARRISON AVENUE BOSTON MA 02118
Business Address 321 HARRISON AVENUE BOSTON MA 02118 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

EIN.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-40881 | Film No.: 23907129
SIC: 2834 Pharmaceutical Preparations